ABBV 8-K Current Reports

AbbVie Inc. 8-K Report, Financial Results (Oct 5, 2026)

AbbVie Inc. (ABBV) has filed an 8-K report to provide an update on its financial outlook, specifically addressing the impact of acquired in-process research and development (IPR&D) and milestones expenses for the third quarter of 2026. The company expects these costs to be approximately $216 million pre-tax, resulting in an unfavorable impact of $0.11 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. These figures are preliminary and subject to final financial closing procedures. The company has reiterated its full-year 2026 adjusted diluted earnings per share guidance range of $13.76 - $13.96, which now incorporates the anticipated impact of the third-quarter IPR&D and milestones expenses. The third-quarter 2026 adjusted diluted earnings per share guidance has been updated to a range of $3.73 - $3.77, reflecting these expenses. AbbVie emphasizes that acquired IPR&D and milestone expenses are difficult to forecast due to the inherent uncertainty in the timing and occurrence of such transactions, and their previously announced guidance excluded such expenses beyond the second quarter of 2026.

Oct 5, 2026 8-K

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Sep 3, 2026)

On September 3, 2026, AbbVie (NYSE: ABBV) announced completion of its acquisition of Apogee Therapeutics (NASDAQ: APGE), with Apogee shareholders receiving $135.11 per share in cash, for a total equity value of approximately $10.9 billion. Apogee's stock ceased trading before market open that day. The deal adds an immunology pipeline led by zumilokibart (APG777), a late-stage, half-life extended anti-IL-13 monoclonal antibody in development for atopic dermatitis, plus APG273, a combination of zumilokibart with APG333 (an anti-TSLP antibody) targeting asthma. For investors, the key financial impact is dilution to near-term earnings. AbbVie expects the acquisition to reduce adjusted diluted EPS by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion not expected until 2032. The company reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 and its third-quarter guidance of $3.84 to $3.88. The 2026 guidance already includes the $0.14 Apogee dilution and $0.58 per share of year-to-date acquired IPR&D and milestone expense through Q2, but excludes any acquired IPR&D and milestone charges beyond Q2 because the company says these cannot be reliably forecast. The filing is a Regulation FD disclosure, so the press release is furnished rather than filed. It carries forward-looking-statement risks, notably the possibility that acquired IPR&D assets do not replicate early clinical results, integration difficulty, and unknown liabilities. The filing does not disclose the deal's financing structure or the effect on AbbVie's balance sheet, so investors should review the company's upcoming filings for those details.

Sep 3, 2026 8-K

AbbVie Inc. 8-K Report, Corporate Update (Aug 18, 2026)

On August 18, 2026, AbbVie completed a $10.0 billion underwritten senior notes offering spanning nine tranches, from 2028 floating-rate notes through 2066 fixed-rate notes. The proceeds are earmarked to help fund the cash consideration for AbbVie's pending acquisition of Apogee Therapeutics, Inc., with any remainder going to general corporate purposes and related fees. The notes were issued under a shelf registration (S-3ASR dated February 14, 2025) and governed by the 2012 base indenture as supplemented by Supplemental Indenture No. 13. The filing is largely a debt-financing disclosure rather than an operating update. The tranche structure is notable: $5.25 billion (roughly 52%) is issued at maturities of 2028 to 2031, while $4.75 billion extends into 2033 through 2066, including $2.0 billion of long-dated 2056 and 2066 notes with coupons of 6.000% and 6.100%. The fixed coupons range from 4.500% to 6.100%, and the pricing curve reflects a meaningfully higher-rate environment at the long end. The 2028 floating-rate tranche and the 2028 fixed-rate notes both mature in August 2028, giving AbbVie a near-term maturity cluster to manage. From an investor standpoint, the key contingent feature is the special mandatory redemption provision. If the Apogee acquisition is terminated or AbbVie informs the trustee it will not pursue it, AbbVie must redeem all notes other than the 2056 and 2066 notes at 101% of principal plus accrued interest. This limits downside for noteholders but also means the acquisition's completion is effectively tied to the debt structure. Investors should watch for closing of the Apogee deal and the resulting increase in AbbVie's total debt load, which the filing does not quantify beyond these offering amounts.

Aug 18, 2026 8-K

AbbVie Inc. 8-K Report, Corporate Update (Aug 5, 2026)

AbbVie Inc. (ABBV) announced through an 8-K filing on August 5, 2026, the closing of a significant debt offering totaling approximately $9.93 billion in net proceeds. This substantial capital raise comprises multiple tranches of senior notes with varying maturities and interest rates, including floating rate notes, fixed-rate notes ranging from 2028 to 2066. The primary purpose of this offering is to fund a portion of the cash payment obligations related to AbbVie's acquisition of Apogee Therapeutics, Inc. This strategic move underscores AbbVie's commitment to its growth strategy through significant M&A activity. The proceeds will also be used for other general corporate purposes, potentially including debt repayment or repurchase, and will reduce commitments under an existing term loan facility established for the Apogee acquisition.

Aug 5, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Jul 31, 2026)

AbbVie reported second-quarter 2026 results that beat expectations on revenue and profitability, led by its immunology franchise. Net revenues rose 10.2% on a reported basis (9.5% operational) to $16.990 billion. Immunology grew 15.1% to $8.786 billion, driven by Skyrizi ($5.505 billion, up 24.4%) and Rinvoq ($2.525 billion, up 24.5%), which offset a 35.9% decline in Humira to $756 million. Neuroscience rose 20.3% to $3.228 billion, with Vraylar, Botox Therapeutic, Ubrelvy/Qulipta and Vyalev all growing. Oncology declined 1.5% to $1.650 billion as Imbruvica fell 29.4%, partly offset by Venclexta and Elahere growth. Aesthetics was roughly flat at $1.282 billion. GAAP diluted EPS was $2.03, up 290.4% from $0.52, while adjusted diluted EPS was $3.65, up 22.9%. Both figures include a $0.17 per-share charge for acquired IPR&D and milestones. The main strategic development is AbbVie's definitive agreement to acquire Apogee Therapeutics, valued at approximately $10.9 billion in total equity. The deal adds zumilokibart (APG777), a late-stage IL-13 antibody for atopic dermatitis, and APG273, a long-acting IL-13/TSLP combination for asthma, and is expected to close in the third quarter of 2026. AbbVie updated its 2026 adjusted diluted EPS guidance to $13.87 to $14.07, from $13.91 to $14.11. The midpoint falls by $0.04 because the Apogee deal is expected to be $0.14 dilutive, partly offset by $0.10 of operational overperformance. The guidance also reflects $0.58 per share of year-to-date acquired IPR&D and milestone expense and excludes any such charges after the second quarter. For investors, the quarter shows strong underlying growth in the Skyrizi and Rinvoq franchises and continued execution in neuroscience, while the Humira and Imbruvica declines and sizable acquisition-related items weigh on the outlook. Key points to monitor are the Apogee closing timeline and integration, Humira and Imbruvica erosion, and the sustainability of the immunology growth rate. The filing does not disclose the deal price per share, financing structure, or any updated pipeline timelines beyond the press release highlights.

Jul 31, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Jul 6, 2026)

AbbVie Inc. (ABBV) has filed an 8-K detailing preliminary second-quarter 2026 financial expectations, specifically addressing the impact of acquired In-Process Research and Development (IPR&D) and milestones expense. The company anticipates a pre-tax charge of $291 million related to these expenses, which is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.17 each. While these are preliminary estimates and subject to final financial closing procedures, investors should note this significant expense impacting near-term profitability. Despite the unfavorable impact from acquired IPR&D and milestones, AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance, now projected to be between $13.91 and $14.11. This revised guidance range incorporates the estimated second-quarter expense. The company also provided a specific second-quarter 2026 adjusted diluted earnings per share guidance range of $3.57 to $3.61, which also includes this expense. Investors are reminded that acquired IPR&D and milestones are inherently unpredictable and are not typically forecasted beyond the initial quarter they are incurred.

Jul 6, 2026 8-K

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Jun 22, 2026)

AbbVie (NYSE: ABBV) has agreed to acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11 per share in cash, a total equity value of approximately $10.9 billion, or about $10.1 billion net of estimated cash and marketable securities acquired. The offer represents a premium of roughly 49% to Apogee's June 18, 2026 closing price. The boards of both companies have unanimously approved the transaction, which is expected to close in the third quarter of 2026, subject to Apogee shareholder approval, regulatory clearances, and other customary conditions. Fairmount Funds and Venrock Associates have already signed voting agreements supporting the deal. The strategic rationale centers on Apogee's lead asset, zumilokibart (APG777), a half-life extended anti-IL-13 antibody in Phase 3-ready development for atopic dermatitis (AD). AbbVie reports positive Phase 2 APEX data, with roughly two-thirds of patients achieving significant skin clearance at 16 weeks, and points to dosing of every 12 or 24 weeks as a convenience differentiator. Phase 3 AD trials are expected to start in the second half of 2026, with potential approval around early 2030. Apogee's broader pipeline, including APG273 (IL-13 plus TSLP combination) in asthma and COPD, extends AbbVie into large respiratory markets. Management characterizes the pipeline as having mega-blockbuster peak sales potential, though the APG273 asset is ascribed modest value given its early stage. Financially, AbbVie will fund the acquisition with debt and expects a negative impact to adjusted diluted EPS of about $0.14 in 2026 and $0.46 in 2027, with accretion beginning in 2032. Management states there is no change to capital allocation priorities, the dividend remains a commitment, and the company expects to maintain its A2/A- credit ratings while targeting 2x net leverage within 2-3 years of closing. The filing is a Regulation FD disclosure, and the forward-looking statements and the risk of clinical, regulatory, and deal-completion failure should be weighed alongside these projections.

Jun 22, 2026 8-K

Shareholder Matters

AbbVie Inc. 8-K Report, Shareholder Vote Results (May 12, 2026)

AbbVie Inc. (ABBV) filed an 8-K on May 12, 2026, detailing the outcomes of its 2026 Annual Meeting of Stockholders held on May 8, 2026. The primary focus of the report is the voting results on several key corporate governance and business matters. Notably, all incumbent Class II directors were re-elected, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 was overwhelmingly ratified. Additionally, stockholders provided advisory approval for the compensation of the company's named executive officers. However, the meeting also saw the rejection of two significant management and stockholder proposals. The proposed amendment to the certificate of incorporation to eliminate supermajority voting requirements did not pass, indicating continued support for existing supermajority provisions among a portion of the shareholder base. Furthermore, a stockholder proposal advocating for a policy to require an independent board chair was also defeated, suggesting that the current board structure without an independent chair is favored by a majority of shareholders or that such a policy was not deemed necessary by a sufficient number of voters.

May 12, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Apr 29, 2026)

AbbVie reported first-quarter 2026 results that beat its internal expectations on the top line and adjusted earnings, and it raised full-year 2026 adjusted diluted EPS guidance. Net revenues were $15.002 billion, up 12.4% reported (10.3% operational), led by Skyrizi (+30.9%) and Rinvoq (+23.3%). Adjusted diluted EPS was $2.65, up 7.7%. Full-year adjusted EPS guidance rose to $14.08-$14.28 from $13.96-$14.16, even after absorbing a $0.41 per-share charge for acquired IPR&D and milestones taken in the quarter. GAAP results were far weaker than the adjusted figures. GAAP diluted EPS fell 45.8% to $0.39 from $0.72, driven mainly by a $2.387 billion pre-tax charge from the change in fair value of contingent consideration ($1.31 per share), $1.748 billion of intangible asset amortization ($0.85 per share), and the $0.41 IPR&D and milestones charge. GAAP operating margin was 26.6% versus an adjusted 40.8%, and the GAAP tax rate was 32.9% versus an adjusted 15.4%. Investors should weigh the adjusted numbers against these large, recurring non-GAAP adjustments. The quarter also brought regulatory and pipeline news. AbbVie submitted applications for Skyrizi subcutaneous induction in Crohn's disease and for Rinvoq in severe alopecia areata. The FDA approved the Venclexta and acalabrutinib combination for previously untreated CLL. A Complete Response Letter for trenibotulinumtoxinE cited only manufacturing questions, not safety or efficacy. AbbVie also announced roughly $1.78 billion in new U.S. manufacturing investment. Offsetting weakness came from Humira (down 38.6%), Imbruvica (down 24.7%), and a flat oncology portfolio.

Apr 29, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Apr 3, 2026)

AbbVie Inc. (ABBV) has filed a Form 8-K to provide preliminary information regarding its first quarter 2026 financial results, specifically detailing the impact of acquired In-Process Research & Development (IPR&D) and milestones expenses. The company anticipates these expenses will negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.41. This expense, totaling $744 million pre-tax, was not previously included in the company's initial 2026 adjusted diluted EPS guidance, which was based on February 4, 2026, expectations. Despite this one-time charge, AbbVie has updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.96 to $14.16, incorporating the first quarter's impact. The updated first quarter 2026 adjusted diluted EPS guidance range is now projected at $2.56 to $2.60. Investors should note that these are preliminary estimates and the final results are subject to financial statement closing procedures. The filing also includes standard forward-looking statement disclaimers highlighting potential risks and uncertainties.

Apr 3, 2026 8-K

AbbVie Inc. 8-K Report, Corporate Update (Mar 4, 2026)

AbbVie Inc. (ABBV) announced the successful completion of a substantial underwritten public offering of senior notes on March 4, 2026. This "Notes Offering" generated a significant amount of capital, totaling approximately $8.0 billion across seven different tranches of debt, including floating rate notes and various fixed-rate notes with maturities ranging from 2028 to 2066. The proceeds from this offering will bolster AbbVie's financial flexibility, potentially to fund future strategic initiatives, acquisitions, or manage existing debt obligations. Investors should note the diverse maturity profile and interest rates associated with these new notes, which indicate a proactive approach by AbbVie in managing its capital structure. The issuance of these notes, registered under a previously filed S-3ASR, signifies AbbVie's ongoing access to public debt markets. The notes are unsecured and rank equally with existing senior unsecured and unsubordinated indebtedness. The company has included customary covenants and redemption provisions, allowing for flexibility in managing these obligations. This move is a standard capital markets activity for a company of AbbVie's size and strategic objectives, and investors should view it within the context of the company's broader financial strategy and capital allocation plans.

Mar 4, 2026 8-K

AbbVie Inc. 8-K Report, Corporate Update (Feb 26, 2026)

AbbVie Inc. (ABBV) announced on February 26, 2026, the successful completion of a significant debt offering totaling approximately $7.95 billion in net proceeds. This offering includes various senior notes with maturities ranging from 2028 to 2066, as well as senior floating rate notes due 2028. The company entered into an underwriting agreement with a syndicate of major financial institutions, including J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC, and Wells Fargo Securities, LLC. The primary purpose of this substantial capital raise is to repay outstanding debt, specifically $2.0 billion currently drawn on a 364-day delayed draw term loan facility maturing in May 2026. The remaining proceeds are designated for general corporate purposes, which may encompass further debt repayment or repurchase. This strategic move signals AbbVie's proactive approach to managing its capital structure and ensuring financial flexibility.

Feb 26, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Feb 4, 2026)

AbbVie reported fourth-quarter and full-year 2025 results on February 4, 2026, showing continued strong top-line growth driven by its immunology and neuroscience franchises, though GAAP earnings were pressured by acquired IPR&D and milestone charges. Full-year net revenues rose 8.6% on a reported basis to $61.16 billion, with Skyrizi ($17.56B), Rinvoq ($8.30B) and Humira ($4.54B) leading immunology revenue of $30.41B, up 14.0%. Neuroscience grew 19.6% to $10.77B, while oncology was nearly flat (+1.5%) and aesthetics declined 6.1%. Fourth-quarter revenue reached $16.62B, up 10.0%, with Skyrizi and Rinvoq growing more than 29%, offset by a 25.9% decline in Humira and a 20.8% decline in Imbruvica. Profitability was mixed. Full-year GAAP diluted EPS fell 1.3% to $2.36, and adjusted diluted EPS fell 1.2% to $10.00. Both figures absorbed an unfavorable $2.76 per share impact from roughly $5.0 billion of acquired IPR&D and milestones expense, which is a recurring feature of AbbVie's business development strategy and makes year-over-year comparisons noisy. Fourth-quarter GAAP EPS was $1.02 versus a GAAP loss in the prior-year period, which had included a large impairment, and adjusted EPS was $2.71 versus $2.16 a year earlier. Management guided 2026 adjusted diluted EPS to $14.37 to $14.57, excluding any future acquired IPR&D and milestone charges. Beyond the financials, the filing highlights a voluntary three-year agreement with the Trump administration covering Medicaid pricing, direct-to-patient offerings, tariff exemption, and a $100 billion U.S. R&D and capital investment commitment over the next decade. The company also disclosed regulatory submissions for Rinvoq in vitiligo and Aquipta in acute migraine in Europe, an FDA approval for Epkinly in follicular lymphoma, a mixed topline result for Epkinly in DLBCL (PFS improved but overall survival did not reach statistical significance), a licensing deal for RemeGen's PD-1/VEGF bispecific RC148, and the acquisition of a device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services.

Feb 4, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Jan 7, 2026)

AbbVie Inc. (ABBV) has filed a Form 8-K disclosing preliminary financial information and guidance updates for the fourth quarter and full year 2025. The company expects to report significant acquired In-Process Research & Development (IPR&D) and milestones expenses totaling $1.3 billion pre-tax for the fourth quarter of 2025. This expense is anticipated to have an unfavorable impact of $0.71 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. This disclosure impacts AbbVie's previously issued guidance. The full-year 2025 adjusted diluted earnings per share guidance has been revised to a range of $9.90 to $9.94, incorporating this expense. Similarly, the fourth-quarter 2025 adjusted diluted earnings per share guidance is now projected to be between $2.61 and $2.65. Investors should note that these figures are preliminary and subject to change as financial closing procedures are completed. The company also reiterates its cautionary note regarding forward-looking statements and the inherent risks and uncertainties in its business operations.

Jan 7, 2026 8-K

AbbVie Inc. 8-K Report, Financial Results (Oct 31, 2025)

AbbVie reported third-quarter 2025 results that were mixed at the headline level: GAAP diluted EPS fell 88.6% to $0.10 and adjusted diluted EPS fell 38.0% to $1.86, but both figures absorbed a $1.50-per-share charge from acquired IPR&D and milestones expense. Underlying top-line momentum was solid. Net revenues rose 9.1% reported (8.4% operational) to $15.776 billion, led by Skyrizi (+46.8% to $4.708 billion) and Rinvoq (+35.3% to $2.184 billion), which more than offset the steep decline in Humira (-55.4% to $993 million) as biosimilar erosion continues. Neuroscience grew 20.2% to $2.841 billion, while Oncology was roughly flat and Aesthetics declined 3.7%. Management raised full-year 2025 adjusted diluted EPS guidance to $10.61–$10.65 from $10.38–$10.58, even after absorbing $2.05 per share of year-to-date IPR&D and milestone charges. The guidance excludes any future IPR&D or milestone charges, which management says cannot be reliably forecast, so the range is effectively a floor relative to deal activity in Q4. The board also approved a 5.5% increase in the quarterly dividend to $1.73 per share, payable February 17, 2026, extending AbbVie's record of dividend growth. The filing also flagged several pipeline and regulatory milestones: FDA approval of an expanded Rinvoq indication in ulcerative colitis and Crohn's disease, positive Phase 3 results in alopecia areata and vitiligo, a head-to-head win over Humira in rheumatoid arthritis, an NDA for tavapadon in Parkinson's disease, and a BLA for pivekimab sunirine. Quarterly GAAP results were also weighed down by an $847 million impairment on Resonic and Durysta intangible assets and a $776 million change in fair value of contingent consideration, and the GAAP tax rate of 73.7% was distorted by these items. Investors should focus on the durability of Skyrizi and Rinvoq growth against the Humira decline, and on the recurring nature of IPR&D charges.

Oct 31, 2025 8-K

AbbVie Inc. 8-K Report, Financial Results (Oct 3, 2025)

AbbVie Inc. (ABBV) has filed an 8-K report on October 3, 2025, providing a preliminary update on its third-quarter 2025 financial results. The company anticipates a significant pre-tax charge of $2.7 billion related to acquired In-Process Research & Development (IPR&D) and milestones. This expense is expected to have an unfavorable impact of $1.50 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. Investors should note that these results are preliminary and subject to finalization. This substantial IPR&D and milestone expense, which AbbVie does not typically forecast due to its unpredictable nature, will adjust the company's full-year 2025 adjusted diluted EPS guidance to a range of $10.38 - $10.58. The third-quarter 2025 adjusted diluted EPS guidance, including this charge, is now projected between $1.74 - $1.78. The company emphasizes that these are estimates and actual results may vary.

Oct 3, 2025 8-K

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Sep 11, 2025)

AbbVie Inc. (ABBV) has announced a significant development concerning its blockbuster drug RINVOQ (upadacitinib tablets). In an 8-K filing dated September 11, 2025, the company disclosed that it has successfully settled litigation with all generic manufacturers who had filed abbreviated new drug applications (ANDAs) for generic versions of upadacitinib tablets. This settlement is a crucial positive development for investors as it significantly extends RINVOQ's market exclusivity. Assuming the granting of pediatric exclusivity, AbbVie expects no generic entry for upadacitinib tablets in the United States prior to April 2037. This extended patent protection provides substantial visibility and stability for a key revenue driver for AbbVie, mitigating near-term patent cliff concerns and reinforcing the long-term commercial potential of this important therapeutic.

Sep 11, 2025 8-K

AbbVie Inc. 8-K Report, Financial Results (Jul 31, 2025)

AbbVie reported second-quarter 2025 results that beat expectations on the top line and raised full-year guidance, though GAAP earnings fell sharply. Net revenues rose 6.6% to $15.423 billion (6.5% on an operational basis), led by Skyrizi (+62.2%) and Rinvoq (+41.8%), which more than offset the steep decline in Humira (-58.1%). Neuroscience grew 24.2%, driven by Botox Therapeutic, Vraylar, Ubrelvy and Qulipta. Aesthetics (-8.1%) and Oncology (+2.6%, with Imbruvica down 9.5%) were weaker. GAAP diluted EPS fell 32.5% to $0.52, from $0.77 a year earlier. The decline reflects a $2.795 billion pre-tax charge from the change in fair value of contingent consideration, $1.864 billion of intangible asset amortization, and $823 million of acquired IPR&D and milestones expense, which cost $0.42 per share. Adjusted diluted EPS rose 12.1% to $2.97. Management raised 2025 adjusted EPS guidance to $11.88–$12.08 from $11.67–$11.87. That range includes a $0.55 per share year-to-date IPR&D and milestones headwind and excludes any such charges incurred after Q2. Pipeline and business development news was active. Highlights included FDA approval of Rinvoq for giant cell arteritis, positive Phase 3 topline data for Rinvoq in severe alopecia areata, an agreement to acquire Capstan Therapeutics (in vivo CAR-T), and an FDA accelerated approval for Emrelis in previously treated NSCLC. Setbacks included the Phase 3 VERONA trial of Venclexta in higher-risk MDS, which missed its overall survival primary endpoint.

Jul 31, 2025 8-K

Leadership ChangesShareholder Matters

AbbVie Inc. 8-K Report, Financial Results (Jul 3, 2025)

AbbVie Inc. (ABBV) has filed a Current Report on Form 8-K on July 3, 2025, to provide an update on its financial outlook for the second quarter and full year of 2025. The report highlights a significant pre-tax expense of $823 million related to acquired in-process research and development (IPR&D) and milestones in the second quarter. This expense is expected to have an unfavorable impact of $0.42 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. While the company's full-year 2025 adjusted diluted earnings per share guidance has been updated to a range of $11.67 - $11.87 to incorporate this expense, investors should note that this IPR&D and milestones expense is inherently unpredictable and was not included in prior guidance beyond the first quarter of 2025. The company is reiterating its second quarter 2025 adjusted diluted earnings per share guidance range as $2.84 - $2.88, inclusive of this newly disclosed expense. Investors are reminded that these are preliminary estimates and final results may differ.

Jul 3, 2025 8-K

AbbVie Inc. 8-K Report, Executive Changes (May 13, 2025)

AbbVie Inc. (ABBV) filed an 8-K on May 12, 2025, detailing significant changes within its Board of Directors and the outcomes of its 2025 Annual Meeting of Stockholders. A key development is the appointment of Thomas J. Falk, former Chairman and CEO of Kimberly-Clark Corporation, as a new independent director to the Board, specifically joining the Audit Committee. This appointment temporarily increases the Board size to fifteen directors. However, the filing also announces a planned reduction in the Board's size back to thirteen directors upon the retirement of Richard A. Gonzalez and Glenn F. Tilton, effective July 1, 2025. This coincides with Robert A. Michael succeeding Mr. Gonzalez as Chairman on the same date. Mr. Michael's compensation has been adjusted to reflect these new responsibilities, with an increased annual bonus target. The annual meeting saw the election of Class I directors, ratification of the independent auditor, and advisory approval of executive compensation. Notably, proposals to eliminate supermajority voting and implement simple majority voting did not pass.

May 13, 2025 8-K

AbbVie Inc. 8-K Report, Financial Results (Apr 25, 2025)

AbbVie reported first-quarter 2025 net revenues of $13.343 billion, up 8.4% on a reported basis and 9.8% on an operational (constant-currency) basis. Growth was led by immunology, where Skyrizi (+70.5%) and Rinvoq (+57.2%) more than offset a 50.6% decline in Humira. Neuroscience (+16.1%) and oncology (+5.8%) also grew, while aesthetics fell 11.7%, with Botox Cosmetic and Juvederm both declining. GAAP diluted EPS was $0.72, down 6.5% from $0.77 a year earlier, while adjusted diluted EPS rose 6.5% to $2.46 from $2.31. The gap is driven mainly by non-cash items excluded from adjusted results: $1.858 billion of intangible asset amortization and a $1.518 billion pre-tax change in the fair value of contingent consideration, which sits in other expense. Acquired IPR&D and milestones cost $0.13 per share in the quarter. GAAP gross margin was 70.0% versus 84.1% adjusted. Management raised full-year 2025 adjusted diluted EPS guidance to $12.09-$12.29 from $11.99-$12.19, a $0.10 increase at both ends of the range. The raised figure already includes the $0.13 year-to-date IPR&D headwind and excludes any future acquired IPR&D, the recently closed Gubra obesity license, and potential pharmaceutical tariffs. Investors should also note that CEO Robert A. Michael will become chairman on July 1, 2025, succeeding Richard A. Gonzalez.

Apr 25, 2025 8-K

AbbVie Inc. 8-K Report, Financial Results (Apr 3, 2025)

AbbVie Inc. (ABBV) filed an 8-K report on April 2, 2025, providing a preliminary update on its first quarter 2025 financial performance. The company expects to incur approximately $248 million in acquired In-Process Research & Development (IPR&D) and milestones expense on a pre-tax basis during the first quarter. This expense is estimated to have an unfavorable impact of $0.13 on both GAAP and adjusted non-GAAP diluted earnings per share (EPS). While this expense was not previously forecasted in the company's initial 2025 guidance, AbbVie has updated its full-year 2025 adjusted diluted EPS guidance to a range of $11.99 - $12.19. The updated first quarter 2025 adjusted diluted EPS guidance is now $2.34 - $2.38. Investors should note that this guidance does not include the impact of the licensing agreement with Gubra for GUB014295, as that transaction closed after the first quarter. The company emphasizes that these are preliminary estimates and actual results are subject to finalization.

Apr 3, 2025 8-K

AbbVie Inc. 8-K Report, Corporate Update (Feb 26, 2025)

AbbVie Inc. (ABBV) has successfully completed a significant underwritten public offering of senior notes totaling $4 billion. This offering includes four tranches with varying maturities and interest rates: $1.25 billion in 4.650% notes due 2028, $1 billion in 4.875% notes due 2030, $1 billion in 5.200% notes due 2035, and $750 million in 5.600% notes due 2055. The issuance was registered under an existing Form S-3ASR registration statement and was finalized on February 25, 2025. These new notes are unsecured, unsubordinated obligations of AbbVie, ranking equally with its existing unsecured debt. The company retains the option to redeem these notes under specific conditions, including at par value after certain dates, with full details outlined in the accompanying indenture. The proceeds from this offering will likely be used to fund corporate activities, potentially including acquisitions, debt refinancing, or general working capital, providing AbbVie with substantial financial flexibility.

Feb 26, 2025 8-K

Leadership ChangesRegulation FDExhibits & Filings

AbbVie Inc. 8-K Report, Corporate Update (Feb 19, 2025)

AbbVie Inc. (ABBV) announced a significant debt financing transaction via an 8-K filing on February 18, 2025. The company has entered into an underwriting agreement to issue and sell approximately $3.98 billion in aggregate principal amount of senior notes across various maturities in 2028, 2030, 2035, and 2055, with coupon rates ranging from 4.650% to 5.600%. These notes are being issued under AbbVie's existing universal shelf registration statement. The primary purpose of this debt issuance is to refinance upcoming maturities of existing senior notes, specifically addressing the 3.600% senior notes due May 2025 ($3.750 billion), 3.800% senior notes due March 2025 ($2.890 billion), and a portion of Allergan Funding SCS's 3.800% senior notes due March 2025 ($130.225 million). This strategic move aims to manage AbbVie's debt profile and secure long-term funding. The net proceeds, after underwriting discounts, are expected to cover these repayment obligations, with any residual funds designated for general corporate purposes.

Feb 19, 2025 8-K

AbbVie Inc. 8-K Report, Executive Changes (Feb 14, 2025)

AbbVie (NYSE: ABBV) filed an 8-K on February 14, 2025 reporting leadership changes at the board level rather than any financial results or operational events. The board unanimously elected Chief Executive Officer Robert A. Michael to succeed Richard A. Gonzalez as Chairman, effective July 1, 2025. Gonzalez, who has chaired the board since the company's formation in 2013, will retire from the board on the same date. Michael will therefore hold both the CEO and Chairman roles, consolidating executive and board leadership in one person. A second board change is also disclosed: Glenn F. Tilton, who served as lead independent director from 2013 to 2024 (succeeded by Roxanne S. Austin in July 2024), will retire as a director effective July 1, 2025. The filing contains no financial data, guidance, or compensation terms for Michael's new role, so investors should look to the proxy statement and future filings for details on governance structure, any changes to director compensation, or succession planning beyond the chairmanship. For investors, the announcement signals continuity: Michael has been with AbbVie for over three decades, served as CFO, vice chairman, and president/COO, and was the executive who navigated the end of Humira exclusivity. The transition appears orderly and planned, with a roughly five-month runway before the effective date. The primary considerations are the concentration of CEO and Chairman roles and whether the board maintains adequate independent oversight, which will be reflected in the company's governance disclosures.

Feb 14, 2025 8-K

Other Events

AbbVie Inc. 8-K Report, Corporate Update (Feb 5, 2025)

AbbVie Inc. (ABBV) has filed an 8-K report on February 5, 2025, detailing the execution of a new $3.0 billion unsecured revolving credit agreement, which matures on January 30, 2030. This new facility, alongside its existing $5.0 billion revolver maturing in March 2028, provides AbbVie with a total of $8.0 billion in available revolving credit. The company had no outstanding borrowings under the new agreement as of its effective date. This strategic move enhances AbbVie's financial flexibility and liquidity, ensuring robust access to capital for general corporate purposes, potential acquisitions, or to manage operational needs. The unsecured nature of the new facility, coupled with its long-term maturity, underscores the company's strong credit standing and confidence in its ongoing financial health. Investors can view this as a positive step towards maintaining operational resilience and strategic agility.

Feb 5, 2025 8-K

AbbVie Inc. 8-K Report, Financial Results (Jan 31, 2025)

AbbVie reported fourth-quarter and full-year 2024 results on January 31, 2025, with a mixed picture: top-line growth remained solid, but GAAP earnings were depressed by large non-cash charges and acquired IPR&D. Full-year 2024 net revenues were $56.334 billion, up 3.7% reported and 4.6% operational, while GAAP diluted EPS fell 12.1% to $2.39 and adjusted diluted EPS fell 8.9% to $10.12. Both figures absorbed an unfavorable $1.52 per share from 2024 acquired IPR&D and milestones expense. Fourth-quarter GAAP diluted EPS was a loss of $0.02, driven by a $3.5 billion after-tax impairment on the emraclidine intangible asset following two failed Phase 2 schizophrenia trials, while adjusted EPS was $2.16 on net revenues of $15.102 billion, up 5.6%. The growth engine continues to shift away from Humira. Skyrizi ($11.718 billion, up 50.9%) and Rinvoq ($5.971 billion, up 50.4%) drove immunology, while Humira fell 37.6% to $8.993 billion after U.S. loss of exclusivity. Neuroscience grew 16.6% to $8.999 billion, led by Vraylar and Botox Therapeutic, and oncology grew 10.8% to $6.555 billion. Aesthetics was the weak spot, declining 2.2%. Management raised its 2027 Skyrizi and Rinvoq outlook to more than $31 billion from more than $27 billion, reaffirmed high single-digit compound annual revenue growth through 2029, and guided 2025 adjusted diluted EPS to $12.12 to $12.32, excluding any future acquired IPR&D charges. For investors, the key questions are the pace of Skyrizi and Rinvoq growth offsetting Humira erosion, the durability of pipeline and business development spending (which continues to generate large IPR&D charges), and the remaining $3.6 billion of intangible assets tied to Cerevel programs that could face further impairment. Pipeline news included positive Phase 3 TEMPO-2 data for tavapadon in Parkinson's disease with an NDA planned for 2025, plus several acquisitions and licensing deals.

Jan 31, 2025 8-K

Financial Events

AbbVie Inc. 8-K Report, Material Impairment (Jan 10, 2025)

AbbVie Inc. (ABBV) announced on January 9, 2025, that it will record a significant non-cash impairment charge of approximately $3.5 billion related to the emraclidine intangible asset. This charge stems from the failure of the two Phase 2 EMPOWER trials to meet their primary endpoints in treating adults with schizophrenia. The trial results, announced on November 11, 2024, indicated that emraclidine did not demonstrate a statistically significant reduction in psychotic symptoms compared to placebo. This impairment charge reflects a substantial decrease in the estimated future cash flows for emraclidine, impacting the carrying value of the intangible asset acquired as part of the Cerevel Therapeutics acquisition. AbbVie is continuing to assess its Cerevel-related clinical development programs and is monitoring the remaining intangible assets, which are valued at approximately $3.6 billion. Investors should note that while this is a significant charge, it is non-cash and does not impact the company's cash position or ongoing operations directly, but it does reflect a setback in a key development program.

Jan 10, 2025 8-K

AbbVie Inc. 8-K Report, Financial Results (Jan 6, 2025)

AbbVie Inc. (ABBV) has filed a Current Report (8-K) on January 6, 2025, providing a crucial update on its financial performance, specifically concerning the fourth quarter of 2024. The company anticipates significant acquired IPR&D (In-Process Research & Development) and milestones expenses, estimated at $1.6 billion on a pre-tax basis. This expense is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.88 each. Investors should note that these are preliminary estimates and the final results may differ. The company has also revised its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.02 - $10.06, incorporating this substantial fourth-quarter expense. The updated fourth-quarter 2024 adjusted diluted earnings per share guidance is now projected to be between $2.06 - $2.10. This filing highlights the financial impact of strategic acquisitions and licensing agreements, which, while strategically important for future growth, introduce a degree of variability and expense that was not previously forecast beyond the third quarter of 2024.

Jan 6, 2025 8-K

Leadership Changes

AbbVie Inc. 8-K Report, Executive Changes (Dec 13, 2024)

This 8-K filing from AbbVie Inc. announces a key executive transition within its finance department. Kevin K. Buckbee, Senior Vice President and Controller, has indicated his planned retirement effective March 1, 2025. This marks the end of Mr. Buckbee's tenure in the Controller role, and the company has appointed David R. Purdue to succeed him. Mr. Purdue, currently Vice President, Controller, Commercial Operations, brings extensive experience within AbbVie and its former parent, Abbott Laboratories. His appointment as Senior Vice President, Controller will be effective on the same date as Mr. Buckbee's retirement. Investors should note Mr. Purdue's new compensation package, including a base salary of $550,000 and eligibility for a performance-based bonus plan, reflecting the importance of this role in financial oversight and strategy.

Dec 13, 2024 8-K

AbbVie Inc. 8-K Report, Financial Results (Oct 30, 2024)

AbbVie's third-quarter 2024 results (8-K Item 2.02, press release dated October 30, 2024) show net revenues of $14.460 billion, up 3.8% reported and 4.9% operationally, driven by strong growth in Skyrizi (+50.8%) and Rinvoq (+45.3%) that offset the continued erosion of Humira (-37.2%). Oncology (+11.6%) and Neuroscience (+15.6%) also grew, while Aesthetics was flat. GAAP diluted EPS fell 12.0% to $0.88 from $1.00, weighed down by a $1.36 billion change in fair value of contingent consideration, $692 million in litigation charges, and $1.89 billion in intangible amortization. Adjusted diluted EPS rose 1.7% to $3.00, and management raised full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, although this range already absorbs a $0.64 per share year-to-date hit from acquired IPR&D and milestones. The quarter's key strategic events were the completion of the Cerevel Therapeutics acquisition, which adds emraclidine (schizophrenia), tavapadon (Parkinson's disease, with positive Phase 3 TEMPO-1 results) and CVL-354 (depression) to the neuroscience pipeline, and a definitive agreement to acquire Aliada Therapeutics, whose lead Alzheimer's asset ALIA-1758 uses blood-brain barrier-crossing technology. The Aliada deal is expected to close in Q4 2024 and is excluded from guidance. Regulatory progress included FDA approval of Vyalev, EC approvals for Skyrizi in ulcerative colitis and Tepkinly, a CHMP positive opinion for Elahere, and a BLA submission for Teliso-V. AbbVie also declared a 5.8% quarterly dividend increase, from $1.55 to $1.64 per share, payable February 14, 2025. Investors should note that GAAP results are heavily affected by acquisition accounting and litigation items, so the gap between GAAP EPS ($0.88) and adjusted EPS ($3.00) is large, and the Humira revenue decline continues to be offset by the growth of newer immunology products.

Oct 30, 2024 8-K

Corporate ChangesExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Oct 3, 2024)

AbbVie Inc. (ABBV) has filed an 8-K report on October 3, 2024, to provide preliminary updates on its third-quarter 2024 financial performance, specifically regarding acquired in-process research and development (IPR&D) and milestones expenses. The company anticipates that these expenses will negatively impact both its GAAP and non-GAAP diluted earnings per share by approximately $0.04 on a pre-tax basis. This filing also revises AbbVie's full-year 2024 adjusted diluted earnings per share guidance to a range of $10.67 - $10.87, incorporating these newly accounted for third-quarter expenses. This disclosure is important for investors as it signals an unplanned increase in R&D-related expenses that affects profitability metrics. While AbbVie typically does not forecast these specific types of expenses due to their unpredictable nature, the company is providing updated guidance to reflect their inclusion. Investors should note that these are preliminary estimates and the final results for the third quarter are subject to the company's financial statement closing procedures.

Oct 3, 2024 8-K

AbbVie Inc. 8-K Report, Bylaw Amendment (Sep 10, 2024)

AbbVie Inc. (ABBV) has filed an 8-K report detailing an amendment to its bylaws, effective September 6, 2024. The key changes involve updating the registered agent's address and removing a specific bylaw provision (Section 2.13(D)(iv)) that was the subject of stockholder litigation. While AbbVie believes the provision was lawful, they have opted to remove it to avoid the expenditure of company resources on its defense, concluding it no longer holds practical value. This filing is administrative in nature and does not directly impact the company's financial performance or strategic operations. Investors should note that the removal of the bylaw provision is a procedural step related to ongoing legal matters rather than an indication of financial distress or a change in business strategy. The full text of the amended bylaws is available as an exhibit to this report.

Sep 10, 2024 8-K

AbbVie Inc. 8-K Report, Financial Results (Jul 25, 2024)

AbbVie reported second-quarter 2024 results that beat its internal expectations, according to CEO Robert A. Michael. Net revenues rose 4.3% reported (5.6% operational) to $14.462 billion. GAAP diluted EPS fell 32.5% to $0.77, while adjusted diluted EPS declined 8.9% to $2.65. Both figures absorbed a $0.52 per-share hit from acquired IPR&D and milestones expense ($937 million pre-tax). The GAAP operating margin was 27.6%, compared with an adjusted operating margin of 42.6%. The GAAP tax rate was 36.0%, versus an adjusted rate of 18.8%. The quarter shows a clear shift in the revenue mix away from Humira. Global Humira sales fell 29.8% to $2.814 billion as U.S. biosimilar competition continued. Growth came from Skyrizi (+44.8% to $2.727 billion) and Rinvoq (+55.8% to $1.430 billion), along with Vraylar, Botox Therapeutic, Venclexta and Qulipta. Management raised its full-year 2024 adjusted diluted EPS guidance to $10.71 to $10.91 from $10.61 to $10.81. The raise includes the $0.60 per-share year-to-date IPR&D and milestones charge, and the guidance excludes any future IPR&D or milestone charges because they cannot be reliably forecast. The filing also covers a leadership change, with Robert A. Michael becoming CEO effective July 1, 2024 and Richard A. Gonzalez becoming executive chairman. It lists several regulatory and pipeline events, including the FDA approval of Skyrizi for ulcerative colitis, a positive CHMP opinion for Skyrizi, the Rinvoq GCA filings, the Epkinly approval in follicular lymphoma, and a Complete Response Letter for ABBV-951 that cited third-party manufacturing inspection observations. The forward-looking statements section also references the pending acquisition of Cerevel Therapeutics.

Jul 25, 2024 8-K

Leadership ChangesShareholder Matters

AbbVie Inc. 8-K Report, Financial Results (Jul 3, 2024)

AbbVie Inc. (ABBV) has filed a Current Report on Form 8-K to provide an update on expected financial results for the second quarter of 2024. The company anticipates reporting acquired intellectual property rights and development (IPR&D) and milestones expenses of $937 million pre-tax. This expense is projected to have an unfavorable impact of $0.52 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. While these figures are preliminary and subject to finalization, AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance. The revised range, now including the impact of the second quarter IPR&D and milestones expense, is between $10.61 and $10.81. The company also provided an updated second quarter 2024 adjusted diluted earnings per share guidance range of $2.53 to $2.57, reflecting this expense. Investors should note that acquired IPR&D and milestones expenses are inherently unpredictable in timing and occurrence, and AbbVie does not typically forecast them beyond the first quarter.

Jul 3, 2024 8-K/A

AbbVie Inc. 8-K/A Report, Executive Changes (May 8, 2024)

This 8-K filing from AbbVie Inc. (ABBV) serves as an amendment and provides crucial updates regarding executive leadership and the outcomes of its 2024 Annual Meeting of Stockholders. The most significant development is the confirmation and detailing of Robert A. Michael's compensation package as he prepares to succeed Richard A. Gonzalez as CEO on July 1, 2024. Mr. Michael will receive a base salary of $1,700,000 and a target bonus of 150% of his base salary. Concurrently, Mr. Gonzalez will transition to Executive Chairman of the Board, with a base salary of $1,500,000 and a target bonus of 140% of his base salary. Furthermore, the filing details the results of the stockholder votes from the May 3, 2024 Annual Meeting. Key outcomes include the election of Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and strong advisory approval for executive compensation. Notably, stockholders voted to hold future "say on pay" votes on an annual basis. However, several management and stockholder proposals, including the elimination of supermajority voting and proposals related to lobbying and patent process reports, did not receive majority approval from stockholders.

May 8, 2024 8-K

AbbVie Inc. 8-K Report, Financial Results (Apr 26, 2024)

AbbVie reported first-quarter 2024 net revenues of $12.310 billion, up 0.7% reported and 1.6% on an operational basis. GAAP diluted EPS was $0.77, up from $0.13 a year earlier, but this reflects a large prior-year charge tied to contingent consideration. Adjusted diluted EPS was $2.31, down 6.1% from $2.46. The adjusted figure excludes $1.89 billion of intangible amortization, $511 million of acquisition and integration costs (mainly ImmunoGen), and a $660 million change in contingent consideration. Management said results were well ahead of its expectations. The quarter shows a sharp mix shift away from Humira. Global Humira sales fell 35.9% to $2.270 billion because of biosimilar competition. Skyrizi (+47.6% to $2.008 billion) and Rinvoq (+59.3% to $1.093 billion) more than offset that decline, and Neuroscience grew 15.9% to $1.965 billion, led by Vraylar, Ubrelvy, and Qulipta. Aesthetics fell 4.0%. The ImmunoGen acquisition closed on February 12, 2024, and contributed $64 million of Elahere revenue in a partial quarter. AbbVie raised its full-year 2024 adjusted EPS guidance to $11.13–$11.33 from $10.97–$11.17, a $0.16 increase at the midpoint. The guidance includes a $0.08 per-share hit from first-quarter acquired IPR&D and milestone expense and excludes any future IPR&D or milestone charges. The filing also announced that Robert A. Michael will succeed Richard A. Gonzalez as CEO effective July 1, 2024, with Gonzalez becoming executive chairman.

Apr 26, 2024 8-K

AbbVie Inc. 8-K Report, Financial Results (Apr 3, 2024)

AbbVie Inc. (ABBV) has filed an 8-K report on April 3, 2024, to provide an update on its financial outlook for the first quarter and full year of 2024. The primary focus of this filing is the impact of acquired In-Process Research & Development (IPR&D) and milestones expenses. AbbVie anticipates these expenses will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08 in the first quarter.

Apr 3, 2024 8-K

Leadership ChangesRegulation FDExhibits & Filings

AbbVie Inc. 8-K Report, Corporate Update (Feb 26, 2024)

AbbVie Inc. (ABBV) announced on February 26, 2024, that it has entered into an underwriting agreement to issue and sell $15.0 billion in aggregate principal amount of senior notes. These notes are offered in various denominations and maturities, ranging from 2027 to 2064, with coupon rates varying from 4.800% to 5.500%. This significant debt issuance is intended to strengthen AbbVie's financial position and fund key strategic initiatives. The primary uses of the net proceeds from this offering are to prepay a $5.0 billion term loan, the proceeds of which were used for the ImmunoGen acquisition, and to fund AbbVie's pending acquisition of Cerevel Therapeutics Holdings, Inc. Additionally, funds will be allocated to repay outstanding commercial paper borrowings and for general corporate purposes. This move indicates a proactive approach by AbbVie to manage its debt structure and finance its growth strategies.

Feb 26, 2024 8-K

AbbVie Inc. 8-K Report, Executive Changes (Feb 20, 2024)

AbbVie (ABBV) filed an 8-K on February 20, 2024 announcing a planned CEO succession. The Board unanimously selected Robert A. Michael, the company's current President and Chief Operating Officer, to succeed Richard A. Gonzalez as CEO, effective July 1, 2024. Gonzalez, who has led AbbVie since its 2013 formation, will become Executive Chairman of the Board on the same date. Michael will also join the Board as a Class II director at that time, and he will receive no additional compensation for his board service. The filing is primarily a governance event rather than a financial one, and it contains no new financial results or guidance. The company describes the transition as a planned, long-prepared succession from an internal candidate, which reduces the risk of an external leadership search. Management stated that the business is performing well and that the pipeline contains multiple candidates to sustain long-term growth. Michael's background, including his roles as CFO and his involvement in the Allergan, ImmunoGen and pending Cerevel transactions, supports continuity in strategy and capital allocation. Investors should still monitor execution during the transition window. Key items to track include the Executive Chairman arrangement, how responsibilities are divided between the two leaders, and whether the strategy and capital allocation priorities remain unchanged. The Cerevel Therapeutics transaction, which the release describes as pending, is also a near-term item to watch. The filing states that the press release is furnished under Item 7.01 and is not deemed filed for Section 18 purposes.

Feb 20, 2024 8-K

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Feb 12, 2024)

On February 12, 2024, AbbVie announced in a Form 8-K (Item 7.01 and Exhibit 99.1) that it had completed its acquisition of ImmunoGen, Inc., adding the flagship antibody-drug conjugate ELAHERE (mirvetuximab soravtansine-gynx) to its portfolio. ELAHERE is approved under accelerated approval for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer, and a confirmatory trial under FDA review reportedly shows a survival benefit. ImmunoGen's Phase 1 FRα ADC IMGN-151 and Phase 2 pivekimab sunirine (anti-CD123, BPDCN, with FDA breakthrough therapy designation) extend the oncology pipeline. Investors should note the price paid: each ImmunoGen share was acquired for $31.26 in cash. Financially, AbbVie reaffirmed its 2024 full-year adjusted diluted EPS guidance of $11.05-$11.25, which now includes a $0.42 per share dilutive impact from the ImmunoGen deal and the pending Cerevel Therapeutics acquisition (expected to close mid-2024). The first-quarter 2024 adjusted diluted EPS guidance was lowered from $2.30-$2.34 to $2.26-$2.30 to reflect a $0.04 per share dilution from ImmunoGen. Management expects the deal to be accretive to diluted EPS beginning in 2027 and significantly accretive over the long term. Guidance excludes acquired IPR&D and milestones, which management says cannot be reliably forecast. The filing is a Regulation FD disclosure, so the press release is not deemed filed under the Exchange Act. Key risks cited include failure to realize anticipated benefits, integration challenges, transaction costs, unknown liabilities, litigation, and intellectual property challenges. ELAHERE carries a boxed warning for severe ocular toxicities and serious adverse reactions in 31% of patients, including fatal events in 2%.

Feb 12, 2024 8-K

AbbVie Inc. 8-K Report, Financial Results (Feb 2, 2024)

AbbVie reported fourth-quarter and full-year 2023 results that were dominated by Humira biosimilar erosion, with GAAP diluted EPS falling sharply while the non-Humira growth platform (Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy/Qulipta) continued to expand. Full-year net revenues were $54.318 billion, down 6.4 percent reported and 5.9 percent operational. Global Humira revenues fell to $14.404 billion for the year, while Skyrizi ($7.763 billion) and Rinvoq ($3.969 billion) grew roughly 50 to 57 percent. GAAP diluted EPS was $2.72 (down 59.0 percent) versus adjusted diluted EPS of $11.11 (down 19.3 percent). The GAAP-to-adjusted gap was driven largely by intangible amortization, a $4.2 billion intangible impairment (including the $2.1 billion Imbruvica charge tied to IRA price negotiation and a $1.0 billion CoolSculpting charge), and a $5.1 billion non-cash contingent consideration fair value change. Management guided 2024 adjusted diluted EPS to $11.05 to $11.25, which includes a $0.32 per share dilution from the pending ImmunoGen (approximately $10.1 billion equity value) and Cerevel Therapeutics (approximately $8.7 billion equity value) acquisitions, both expected to close in mid-2024. The guidance excludes any future acquired IPR&D and milestone charges. Management reaffirmed a high single-digit revenue CAGR through 2029 with 2024 as the base year, and raised its 2027 Skyrizi plus Rinvoq outlook to more than $27 billion from more than $21 billion, and its Ubrelvy plus Qulipta peak sales outlook to more than $3 billion combined. For investors, the key tension is between a shrinking legacy Humira franchise and a growing newer portfolio that must absorb that erosion, alongside a meaningful increase in R&D spending and a large acquisition program that adds dilution in 2024 and raises execution and integration risk. The filing is a press release furnished under Item 2.02, so the figures are unaudited for the quarter and reflect the company's own non-GAAP presentation.

Feb 2, 2024 8-K

AbbVie Inc. 8-K Report, Financial Results (Jan 5, 2024)

AbbVie Inc. (ABBV) has filed a Current Report (8-K) on January 5, 2024, to provide an update on its expected financial results for the fourth quarter of 2023. The company anticipates an unfavorable impact of $282 million (pre-tax) from acquired in-process research and development (IPR&D) and milestones expense. This expense is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share (EPS) by approximately $0.15. While these are preliminary estimates and subject to change, AbbVie has updated its full-year 2023 adjusted diluted EPS guidance to a range of $11.04 - $11.08, and its fourth-quarter 2023 adjusted diluted EPS guidance to $2.72 - $2.76. Investors should note that this expense was not included in previous guidance for the period beyond the third quarter of 2023. The company also reminds investors of the inherent risks and uncertainties associated with its business and forward-looking statements.

Jan 5, 2024 8-K

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Dec 6, 2023)

On December 6, 2023, AbbVie Inc. (ABBV) announced a definitive agreement to acquire Cerevel Therapeutics (CERE) for $45.00 per share in cash, implying a total equity value of approximately $8.7 billion (about $8.4 billion net of estimated cash acquired). The price represents a premium of roughly 73% to Cerevel's unaffected closing price on December 1, 2023. The deal is expected to close in mid-2024, subject to Cerevel shareholder approval, regulatory clearances, and customary closing conditions. AbbVie will fund the transaction with a combination of cash and debt. The strategic rationale centers on adding Cerevel's clinical-stage neuroscience pipeline to AbbVie's existing neuroscience franchise. The most important asset is emraclidine, an M4 muscarinic positive allosteric modulator in schizophrenia, which AbbVie describes as the largest component of deal value. Two Phase 2 trials are ongoing with data expected in 2H24. Other assets include tavapadon (D1/D5 partial agonist in Phase 3 for Parkinson's disease, with data expected in 2024), CVL-354 (kappa opioid receptor antagonist for major depressive disorder, Phase 1), and darigabat (GABAA PAM in Phase 2 for epilepsy and panic disorder). Management frames these as multibillion-dollar peak sales opportunities for emraclidine and CVL-354 combined. For investors, the key trade-off is near-term earnings dilution against long-term growth. AbbVie expects the deal to reduce adjusted diluted EPS by about $0.19 in 2024 and about $0.41 in 2025, with positive operating margin in 2028 and EPS accretion beginning in 2030. AbbVie reaffirmed its $11.00 adjusted diluted EPS floor for 2024, inclusive of the Cerevel and ImmunoGen transactions, and stated no change to its capital allocation priorities, dividend growth commitment, or target of 2x net leverage by end of 2026. The filing itself is a Regulation FD disclosure, and the forward-looking risks flagged include regulatory approval, shareholder vote, integration, financing, and clinical and litigation risk.

Dec 6, 2023 8-K

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Nov 30, 2023)

AbbVie Inc. (ABBV) has agreed to acquire ImmunoGen, Inc. (IMGN) in an all-cash deal priced at $31.26 per share, valuing ImmunoGen's equity at approximately $10.1 billion (about $9.8 billion net of estimated cash acquired). The price represents a premium of roughly 95% to ImmunoGen's November 29, 2023 closing price. The central asset is ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class folate receptor alpha (FRα)-directed antibody-drug conjugate approved under accelerated approval for platinum-resistant ovarian cancer. Management frames ELAHERE as a de-risked, on-market product with a Phase 3 MIRASOL overall survival benefit, and sees it as a potential multi-billion-dollar franchise as label expansion into earlier lines and FRα-medium patients proceeds over the next 5-10 years. Financially, AbbVie expects the deal to be a modest EPS headwind: roughly -$0.13 to adjusted diluted EPS in 2024 (partial year, assuming a 2Q24 close) and -$0.16 in 2025, neutral in 2026, and accretive thereafter. AbbVie reaffirmed an adjusted diluted EPS floor of $11.00 for 2024 inclusive of the deal's impact, and stated no change to its capital allocation priorities, including its dividend policy and its A3/A credit rating target. The transaction will be funded with a combination of cash and debt, and closing is expected in mid-2024, subject to ImmunoGen shareholder approval, regulatory clearances, and customary conditions. The filing itself is a Regulation FD disclosure (Item 7.01) attaching the joint press release and investor presentation; the deal's value attribution is weighted heavily toward ELAHERE, with only modest value ascribed to the earlier-stage IMGN-151 and pivekimab sunirine.

Nov 30, 2023 8-K

AbbVie Inc. 8-K Report, Financial Results (Oct 27, 2023)

AbbVie reported third-quarter 2023 results that were mixed on the surface but reflected a strong non-Humira growth engine. Net revenues were $13.927 billion, down 6.0% reported (5.8% operational), as Humira fell 36.2% to $3.547 billion amid biosimilar erosion. GAAP diluted EPS was $1.00, down 54.8%, driven largely by a $2.1 billion pre-tax partial impairment of the U.S. Imbruvica intangible asset following its selection for Medicare price negotiation under the Inflation Reduction Act. Adjusted diluted EPS was $2.95, down 19.4%, and includes a $0.04 unfavorable impact from acquired IPR&D and milestones expense. The GAAP figures should be weighed against the adjusted figures, which exclude large non-cash amortization charges, so investors should focus on the underlying trajectory rather than the headline GAAP decline. The non-Humira portfolio continued to accelerate. Skyrizi grew 52.1% to $2.126 billion and Rinvoq grew 59.8% to $1.110 billion, together offsetting much of the Humira decline. Neuroscience revenue rose 22.1% to $2.043 billion, led by Vraylar and Botox Therapeutic, while Oncology declined 8.4% as Imbruvica fell 20.0%. Management raised 2023 adjusted EPS guidance to $11.19–$11.23 (from $10.86–$11.06), net of the year-to-date IPR&D charge, and raised the 2024 adjusted EPS floor to $11.00 from $10.70, excluding IPR&D and milestones. AbbVie also increased its quarterly dividend 4.7% to $1.55 per share, starting with the February 2024 payment. Key watch items include the Imbruvica IRA-driven impairment and the remaining $1.8 billion carrying value of that intangible, the CANOVA Phase 3 miss for Venclexta in multiple myeloma, and the pace at which Skyrizi and Rinvoq can replace Humira revenue. Regulatory and pipeline catalysts include filings for Skyrizi in ulcerative colitis, the SEQUENCE Phase 3 win versus Stelara in Crohn's disease, and advancement of Rinvoq into Phase 3 for vitiligo.

Oct 27, 2023 8-K

Leadership Changes

AbbVie Inc. 8-K Report, Executive Changes (Oct 12, 2023)

AbbVie Inc. (ABBV) announced an expansion of its Board of Directors, increasing its size from eleven to thirteen members. This strategic move involves the appointment of two new independent directors: Jennifer Davis, CEO of Health Care at Procter & Gamble, and Susan Quaggin, Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine. The addition of these directors, who bring extensive experience in consumer health and medical leadership respectively, is intended to enhance the Board's expertise and oversight capabilities. Ms. Davis has been appointed to the Nominations and Governance Committee, while Dr. Quaggin will serve on the Public Policy and Sustainability Committee. Both directors have been deemed independent by the Board according to NYSE and AbbVie's internal guidelines. Investors can expect these appointments to contribute to the company's strategic direction and governance, leveraging their distinct professional backgrounds to further AbbVie's long-term objectives.

Oct 12, 2023 8-K

AbbVie Inc. 8-K Report, Financial Results (Oct 4, 2023)

AbbVie Inc. (ABBV) has filed an 8-K report providing preliminary financial insights for the third quarter of 2023, ending September 30, 2023. The company expects acquired In-Process Research & Development (IPR&D) and milestones expenses to negatively impact both GAAP and non-GAAP diluted earnings per share by $0.04 on a pre-tax basis. This expense, totaling $66 million, was not previously forecasted due to its uncertain nature. While these are preliminary estimates and final results may vary, AbbVie has updated its full-year and third-quarter adjusted diluted earnings per share guidance to reflect this event. The updated full-year 2023 adjusted diluted EPS guidance is now projected to be in the range of $10.86 to $11.06, and the third-quarter 2023 adjusted diluted EPS guidance is revised to $2.76 to $2.86. Investors should note that the information furnished in this report is not considered 'Filed' and therefore does not carry the same liability as traditional SEC filings, but it provides important context for the company's current financial outlook.

Oct 4, 2023 8-K